ATE391499T1 - 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen - Google Patents

4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen

Info

Publication number
ATE391499T1
ATE391499T1 AT05716433T AT05716433T ATE391499T1 AT E391499 T1 ATE391499 T1 AT E391499T1 AT 05716433 T AT05716433 T AT 05716433T AT 05716433 T AT05716433 T AT 05716433T AT E391499 T1 ATE391499 T1 AT E391499T1
Authority
AT
Austria
Prior art keywords
benigon
hydroxytamoxifen
prophylaxis
treatment
benign breast
Prior art date
Application number
AT05716433T
Other languages
English (en)
Inventor
Nestour Elisabeth Le
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04290761A external-priority patent/EP1579856A1/de
Priority claimed from US10/805,528 external-priority patent/US7507769B2/en
Application filed by Besins Int Lab filed Critical Besins Int Lab
Application granted granted Critical
Publication of ATE391499T1 publication Critical patent/ATE391499T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT05716433T 2004-03-22 2005-03-10 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen ATE391499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290761A EP1579856A1 (de) 2004-03-22 2004-03-22 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
US10/805,528 US7507769B2 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
ATE391499T1 true ATE391499T1 (de) 2008-04-15

Family

ID=34961912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716433T ATE391499T1 (de) 2004-03-22 2005-03-10 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen

Country Status (17)

Country Link
EP (1) EP1748770B1 (de)
JP (1) JP5072588B2 (de)
CN (1) CN1946387B (de)
AT (1) ATE391499T1 (de)
AU (1) AU2005227072B2 (de)
CA (1) CA2559748C (de)
DE (1) DE602005005986T2 (de)
DK (1) DK1748770T3 (de)
ES (1) ES2306111T3 (de)
HK (1) HK1096595A1 (de)
MX (1) MXPA06010914A (de)
NO (1) NO336767B1 (de)
NZ (1) NZ549817A (de)
PL (1) PL1748770T3 (de)
PT (1) PT1748770E (de)
RU (1) RU2357726C2 (de)
WO (1) WO2005092309A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE415156T1 (de) * 2004-10-14 2008-12-15 Besins Int Lab 4-hydroxytamoxifengel-formulierungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
ES2330188T3 (es) * 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
AU2003294973B2 (en) * 2002-12-18 2010-05-13 Besins Healthcare Luxembourg Sarl Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
AU2003303033B2 (en) * 2002-12-18 2009-06-04 Besins Healthcare Luxembourg Sarl Treatment of mastalgia with 4-hydroxy tamoxifen
DK1694319T3 (da) * 2003-12-15 2008-11-17 Besins Int Lab Anvendelser af 4-hydroxytamoxifen til fremstilling af et medikament til behandling af gynækomasti

Also Published As

Publication number Publication date
EP1748770B1 (de) 2008-04-09
CA2559748A1 (en) 2005-10-06
ES2306111T3 (es) 2008-11-01
JP5072588B2 (ja) 2012-11-14
DK1748770T3 (da) 2008-08-04
CA2559748C (en) 2013-05-28
DE602005005986D1 (de) 2008-05-21
CN1946387B (zh) 2011-08-31
MXPA06010914A (es) 2006-12-15
RU2357726C2 (ru) 2009-06-10
DE602005005986T2 (de) 2009-06-04
AU2005227072B2 (en) 2010-08-19
AU2005227072A1 (en) 2005-10-06
JP2007535505A (ja) 2007-12-06
NO20064609L (no) 2006-10-11
HK1096595A1 (en) 2007-06-08
NZ549817A (en) 2010-06-25
CN1946387A (zh) 2007-04-11
PT1748770E (pt) 2008-07-16
WO2005092309A1 (en) 2005-10-06
PL1748770T3 (pl) 2008-09-30
RU2006137280A (ru) 2008-04-27
NO336767B1 (no) 2015-10-26
EP1748770A1 (de) 2007-02-07

Similar Documents

Publication Publication Date Title
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
Cohen et al. The bright side of ascites in ovarian cancer
SE0300098D0 (sv) Use of cyclin D1 inhibitors
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
Sefu et al. Human nasal rhinosporidiosis: a case report from Malawi
EA201270298A1 (ru) Способ лечения злокачественной опухоли
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
ATE391499T1 (de) 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
MA33579B1 (fr) Thérapie anti-angiogenèse pour le traitement d'un cancer du sein précédemment traité
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
Swapnil et al. Targeted Drug Delivery: A Backbone for Cancer Therapy
Dehghani Firoozabadi et al. Prevention of nausea and vomiting: methods and utility after surgery in cancer patients?
Salim et al. Erythema multiforme associated with Trichophyton mentagrophytes infection.
RU2222319C2 (ru) Способ регионарной лимфостимуляции и обезболивания при лимфедеме нижних конечностей
Son et al. A Clinical study of according to prevalence of dermatoses in a oriental medicine hospital of Gang-Dong Area in seoul
Magram et al. Acupuncture and Cancer Pain
Silva et al. Non-Hodgkin Lymphoma: Presentation of a Case with Oral Manifestations
BR112012013719A2 (pt) uso de transferrina no tratamento de ß-talassemias
ATE403424T1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
DVT et al. The Impacts of Head & Neck Lymphedema

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1748770

Country of ref document: EP